US biotech company Ambit, set up in 2000, develops little molecular kinase blockers for treating cancer. Using its proprietary KinomeScan technology, Ambit produces uniform, detailed kinase (enzymes) profiles, which serve to develop more targeted drugs with minimum side effects. Many of Ambit’s drugs are at the preclinical and clinical research stages. These include AC220, a kinase blocker for treating an acute form of leukaemia. The company maintains partnerships with prominent companies like Roche, Pfizer and GlaxoSmithKline.
- Aktivität: Functional proteomics
- Website: www.ambitbio.com
- Investititionsjahr: 2002
- Plattform: Health & Care